Alpha Cancer Technologies (ACT) is a clinical-stage biotechnology company focused on developing innovative therapies for cancer and autoimmune diseases through its proprietary platforms, which include Immuno-Oncology, Radiopharmaceuticals, and Immunomodulation. Central to their approach is the use of recombinant human alpha fetoprotein (AFP), which has shown safety in over 300 patients and is being utilized in various preclinical and clinical studies. The company is advancing several lead assets, including ACT-901, ACT-902, and ACT-903, which combine AFP with potent chemotherapy agents like paclitaxel and maytansine. These targeted therapies aim to selectively deliver treatment to cancer cells, exploiting the presence of AFP receptors on over 80% of solid and liquid tumors while sparing healthy cells, thereby minimizing toxicity and enhancing efficacy.

In addition to its targeted immuno-oncology efforts, ACT is also exploring the potential of AFP in immunomodulation for conditions such as Myasthenia Gravis and Inflammatory Bowel Disease. The company is preparing for Phase II trials for these indications and is seeking to outlicense its immunomodulation platform. With significant investment backing and collaborations with leading research institutions, ACT is positioned to make substantial advancements in cancer treatment, leveraging its unique understanding of AFP's role in both targeting cancer cells and modulating immune responses.

Canada

Alpha Cancer Technologies Inc. (ACT) is a private clinical stage biotechnology company with platform technologies in Immunotherapy and Immuno-Oncology. These platforms under development treat auto-immune disease indications and cancer. The company’s drug products use our proprietary recombinant human alpha fetoprotein (AFP).

Alpha Cancer Technologies

Company Details